Table 1.

Demographic and tumor characteristics of CA and AA prostate cancer cases in PCap

CA (n = 1,012)AA (n = 918)P
Age at diagnosis, mean (SD)64 (8)62 (8)<0.0001
Site
 North Carolina479 (47)448 (49)0.519
 Louisiana533 (53)470 (51)
Clinical stage
 T1559 (55)509 (55)0.926
 T2–T4453 (45)409 (45)
PSA (ng/mL), median (IQR)5.2 (4.1–7.5)6.2 (4.5–10.7)<0.0001
Biopsy Gleason sum
 ≤3+4829 (82)702 (77)0.006
 ≥4+3180 (18)208 (23)
Aggressive prostate cancer
 Low/intermediate861 (85)725 (79)<0.0001
 High151 (15)193 (21)
Prostate cancer screening frequency
 Never116 (11)328 (36)<0.0001
 ≤1 test per year386 (38)377 (75)
 >1 test per year510 (50)123 (25)
Family history of prostate cancer (first-degree relative)a
 No706 (75)608 (72)0.122
 Yes232 (25)236 (28)
Education
 Less than high school94 (9)265 (29)<0.0001
 High school graduate212 (21)258 (28)
 College graduate or some college706 (70)394 (43)
Incomeb
 <$20,00091 (10)273 (32)<0.0001
 $20,000–$50,000268 (29)327 (39)
 $50,000–$80,000229 (25)137 (16)
 >$80,000337 (36)105 (12)
Smoking status
 Never367 (36)283 (31)<0.0001
 Former551 (54)441 (48)
 Current94 (9)194 (21)
BMI (kg/m2)
 <30635 (63)558 (61)0.375
 ≥30377 (37)360 (39)
Charlson comorbidity index
 0542 (54)436 (47)0.008
 ≥1470 (46)482 (53)
Cardiovascular disease
 No821 (81)791 (87)0.001
 Yes187 (19)118 (13)
Diabetes
 No842 (84)674 (74)<0.0001
 Yes166 (16)239 (26)
Dietary cholesterol intake (mg/day), median (IQR)262 (180–355)302 (206–439)<0.0001
Percent saturated fat intake, mean (SD)11.2 (2.7)10.0 (2.6)<0.0001
Nonstatin cholesterol-lowering drug use
 None842 (83)844 (92)<0.0001
 Niacin/fibrate/ezetimibe170 (17)74 (8)

Abbreviation: IQR, interquartile range.

  • aFamily history was missing for 74 CA and 74 AA men.

  • bIncome was missing for 12 CA and 31 AA men, whereas 75 CA and 45 AA men refused to answer this question.